Immune Pharmaceuticals is on a mission to improve patients’ lives through targeted medicine. The company is well-funded by a diverse investment base. Clinical work focuses on severe and/or rare inflammatory diseases and cancer.
What Many Investors May Not Know About IMNP:
- Our lead asset, Bertilimumab, is a first in class antibody, with on going phase 2 trials in multiple indications and potential sales of $ 5B per year
- Our Immuno-Oncology pipeline, includes 3 mid-to-late stage assets and two platforms with a focus on check point inhibitors.
- NanoCyclo is a potentially game changing topical treatment for atopic dermatitis and psoriasis with potential sales of $1B and 505(b)2 accelerated track.
- IMNP NYC based new management team is poised for execution with multiple 2016-17 milestones.
Information to the Swedish Markets, June 2015
Holdings of Insiders, as of latest reported date
| Insider Name | Relationship | Total Holdings |
| Teper, Daniel Gedeon | Chief Executive Officer | 5,865,280 |
| Kazado, Daniel | Director | 907,290 |
| Luchi, Monica E | Officer | 777,778 |
| Paley, Jeffrey | Director | 8,000 |
| Militello, John CPA | Officer | 2,000 |
| Neczesny, John A | Director | 0 |
| Ben-Ami, Miri | Officer | 0 |